Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis

被引:1
|
作者
Hayashi, Hironori [1 ]
Amaya, Koji [1 ]
Tokoro, Tomokazu [1 ]
Mori, Kosuke [1 ]
Takenaka, Shunsuke [1 ]
Sugimoto, Yuya [1 ]
Kitano, Yuto [1 ]
Kurata, Toru [1 ]
Kawai, Shunsuke [1 ]
Hirose, Atsushi [1 ]
Tsukada, Tomoya [1 ]
Kaji, Masahide [1 ]
Shimizu, Koichi [2 ]
Maeda, Kiichi [1 ]
机构
[1] Toyama Prefectural Cent Hosp, Dept Surg, 2-2-78 Nishi Nagae, Toyama 9308550, Japan
[2] Kaga Med Ctr, Dept Surg, Kaga, Ishikawa 9228522, Japan
关键词
cancer genomics; epidemiology; multiple primary malignancies; pancreatic ductal adenocarcinoma; prognosis; surgical treatment; CANCER PATIENTS; ORGANS; IMPACT;
D O I
10.3892/mco.2021.2.335
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with pancreatic ductal adenocarcinoma (PDAC) that have a history of other primary malignancies are not well documented. The current study therefore aimed to evaluate the dinicopathological characteristics of patients with PDAC with or without a history of other primary malignancies. A total of 102 patients with surgically treated PDAC that presented with or without a history of other primary malignancies were retrospectively analyzed. A total of 25 patients (24.5%) had a history of other primary malignancies (age, with history of other primary malignancy vs. without, 74.2 vs. 68.9 years; P=0.005) and the reason for consultation (P<0.001) differed significantly between the groups with a history of other primary malignancies [FloM(+)] and without a history of other primary malignancies [HOMO]. Incidental indications during malignancy follow-up was the most common reason for the diagnosis of PDAC in the HoM(+) group. Conversely, there were no significant differences in the resectability (P=0.645), complete resection rate (P=0.774) and final stage (P=0.474) between the two groups. Disease-free survival was also not significantly different between the two groups (P=0.184). However, overall survival was significantly poorer in the HoM(+) group compared with the HoM(-) group (P=0.003). A history of other primary malignancies was also an independent predictor of poor overall survival (hazard ratio, 2.416; 95% confidence interval, 1.324-4.406; P=0.004). In conclusion, patients with PDAC and a history of other primary malignancies had significantly poorer overall survival than their counterparts, despite no differences in disease-free survival.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma
    Komura, Takuya
    Takabatake, Hisashi
    Harada, Kenichi
    Yamato, Masatoshi
    Miyazawa, Masaki
    Yoshida, Keiko
    Honda, Masao
    Wada, Takashi
    Kitagawa, Hirohisa
    Ohta, Tetsuo
    Kaneko, Shuichi
    Sakai, Yoshio
    CANCER SCIENCE, 2017, 108 (11): : 2122 - 2129
  • [2] Clinical Features of Multiple Primary Malignancies: a Retrospective Analysis of 72 Chinese Patients
    Jiao, Feng
    Yao, Li-Juan
    Zhou, Jin
    Hu, Hai
    Wang, Li-Wei
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (01) : 331 - 334
  • [3] Clinical features of young patients (below age 40) with pancreatic ductal adenocarcinoma
    Ohmoto, Akihiro
    Morizane, Chigusa
    Kubo, Emi
    Shimada, Kazuaki
    Okusaka, Takuji
    Yachida, Shinichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [4] Clinical Features and Prognostic Impact of Pancreatic Ductal Adenocarcinoma without Dilatation of the Main Pancreatic Duct: A Single-Center Retrospective Analysis
    Takayanagi, Takuya
    Sekino, Yusuke
    Kasuga, Noriki
    Ishii, Ken
    Nagase, Hajime
    Nakajima, Atsushi
    DIAGNOSTICS, 2023, 13 (05)
  • [5] Cytoglobin as a Prognostic Factor for Pancreatic Ductal Adenocarcinoma A Retrospective Analysis of 75 Patients
    Kono, Hiroshi
    Hosomura, Naohiro
    Amemiya, Hidetake
    Kawaida, Hiromichi
    Furuya, Shinji
    Akaike, Hidenori
    Kawaguchi, Yoshihiko
    Sudo, Makoto
    Ichikawa, Daisuke
    PANCREAS, 2021, 50 (07) : 994 - 999
  • [6] Clinical Features of Trousseau Syndrome Associated With Pancreatic Ductal Adenocarcinoma
    Kusaka, H.
    Yoshida, K.
    Nakashima, Y.
    Aoki, H.
    Tokioka, S.
    Nishimon, R.
    Kitagawa, A.
    Hino, K.
    PANCREAS, 2019, 48 (10) : 1469 - 1469
  • [7] Features of immunophenotype of pancreatic ductal adenocarcinoma
    Evseyev, A. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2014, (06) : 87 - 89
  • [8] Germline Pathogenic Variants in Patients with Pancreatic Ductal Adenocarcinoma and Extra-Pancreatic Malignancies: A Nationwide Database Analysis
    Kryklyva, Valentyna
    Pfluger, Michael J.
    Ouchene, Hicham
    Volleberg-Gorissen, Hanneke
    Mensenkamp, Arjen R.
    Jonker, Marianne A.
    van de Water, Carlijn
    Nagtegaal, Iris D.
    Ligtenberg, Marjolijn J. L.
    Brosens, Lodewijk A. A.
    MODERN PATHOLOGY, 2025, 38 (05)
  • [9] Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis
    Puri, Akshjot
    Chang, John
    Tanner, Natalee
    Lucente, Patricia
    Desiongco, Janice
    Dragovich, Tomislav
    Naraev, Boris
    Kundranda, Madappa
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (02) : 455 - 463
  • [10] Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma
    Shutaro Hori
    Kazuaki Shimada
    Yoshinori Ino
    Seiji Oguro
    Minoru Esaki
    Satoshi Nara
    Yoji Kishi
    Tomoo Kosuge
    Yukinori Hattori
    Aoi Sukeda
    Yuko Kitagawa
    Yae Kanai
    Nobuyoshi Hiraoka
    Virchows Archiv, 2016, 469 : 621 - 634